Literature DB >> 19687730

Pituitary adenoma: a radiotherapeutic perspective.

Christopher S Platta1, Christopher Mackay, James S Welsh.   

Abstract

Pituitary adenomas comprise approximately 10% to 20% of all central nervous system neoplasms whereas autopsy series have suggested that the incidence of pituitary adenoma in the general population may approach 25%. Several treatment modalities are used in the treatment of pituitary adenomas, including observation, surgery, medical intervention, and radiotherapy. The treatment modality employed depends greatly on the type of pituitary adenoma and presenting symptoms. This review will discuss the biology of pituitary adenomas and the current management principles for the treatment of prolactinomas, Cushing disease, acromegaly, and nonsecretory adenomas, with an emphasis on the published radiotherapeutic literature.

Entities:  

Mesh:

Year:  2010        PMID: 19687730     DOI: 10.1097/COC.0b013e31819d878d

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  Outcome of radiotherapy for pituitary adenomas.

Authors:  Patricia Sebastian; Rajesh Balakrishnan; Bijesh Yadav; Subhashini John
Journal:  Rep Pract Oncol Radiother       Date:  2016-07-15

2.  Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes.

Authors:  Raj Singh; Prabhanjan Didwania; Eric J Lehrer; Darrah Sheehan; Kimball Sheehan; Daniel M Trifiletti; Jason P Sheehan
Journal:  J Neurooncol       Date:  2020-06-06       Impact factor: 4.130

3.  Long non-coding RNA TUG1/microRNA-187-3p/TESC axis modulates progression of pituitary adenoma via regulating the NF-κB signaling pathway.

Authors:  Rui Zhang; Fan Yang; Haitao Fan; Haocong Wang; Qinghao Wang; Jianxin Yang; Tao Song
Journal:  Cell Death Dis       Date:  2021-05-21       Impact factor: 8.469

4.  Effect of treatment modality on the hypothalamic-pituitary function of patients treated with radiation therapy for pituitary adenomas: hypothalamic dose and endocrine outcomes.

Authors:  Andrew Elson; Joseph Bovi; Kawaljeet Kaur; Diana Maas; Grant Sinson; Chris Schultz
Journal:  Front Oncol       Date:  2014-04-09       Impact factor: 6.244

5.  Treatment of benign tumours and related pathologies with radiotherapy: experience of the General Hospital of Mexico.

Authors:  Yicel Bautista Hernandez; Karina Vazquez Gomez; Ana Laura Lopez
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.